LamdaGen Corporation Forms Strategic Advisory Board – Appoints Industry Leaders in Diagnostic Innovation as Inaugural Members

MENLO PARK, CA, June 22, 2023— LamdaGen Corporation, an emerging diagnostic technology company with a powerful, plasmonic platform for rapid diagnostic/detection testing, is pleased to announce the members of its newly-formed Strategic Advisory Board (SAB).

The inaugural SAB members represent a distinguished set of experts who bring a depth and breadth of leadership, innovation and product commercialization experience in the life science, diagnostic, pharmaceutical and food safety industries.

“We are honored to be working with a team of respected and knowledgeable individuals whose areas of industry expertise are directly related to the work we have underway,” commented Randolph Storer, CEO and co-founder of LamdaGen Corporation. “Their insights will significantly help us leverage the progress our team has made, and guide the company towards bringing innovative, highly sensitive, rapid diagnostic solutions to market.”

The company welcomes Dr. Richard Eglen, as Chairman, and John Verrant and Dr. Martin Easter who join LamdaGen’s CEO and co-founder, Randolph Storer on the SAB.

Dr. Richard Eglen is a distinguished veteran of the pharmaceutical, diagnostic, and biotech industries and has held numerous executive management positions over the past 40 years. His past leadership roles include Vice President and General Manager of Corning Life Sciences, President of Bio-discovery at PerkinElmer, Executive Vice President for research and development at DiscoveRx Corp, and Vice President of the Center for Biological Research at Roche Pharmaceuticals. He has authored more than 320 publications, book chapters, and patents, and serves on several industry, academic advisory, and journal editorial boards. He is a Fellow of the Society for Laboratory Automation and Screening (SLAS), as well as a previous Board member and past President of the Society.

John Verrant is a seasoned executive and technical leader in medical device and diagnostics development, with hands-on experience taking new technologies from platform development through to product launch. Mr. Verrant recently retired as Senior Principal Scientist, Medical Digital & Technical Solutions Infectious Diseases at Janssen/Johnson & Johnson, where he led efforts at Janssen implementing digital and diagnostic solutions into clinical trials, and mentored early stage/emerging companies towards commercialization. Mr. Verrant has held engineering and product development leadership roles with Abbott Diagnostics, Abbott Point of Care and others, bringing forward innovative optical detection systems.

Dr. Martin Easter is the Co-Founder and recently retired Chief Scientific Officer of Hygiena, a global developer, producer and provider of best-in-class food safety diagnostic solutions throughout the farm-to-fork value chain. Dr. Easter pioneered the development of rapid test methods based on ATP bioluminescence for the Food Safety industry, which was integral to revolutionizing ATP hygiene testing with improved performance, reliability and affordability. He and has over 35 years of experience in the industry as a business leader and industrial microbiologist innovator.

About LamdaGen Corporation

LamdaGen Corporation is an innovative technology holding company at the forefront of developing and integrating powerful plasmonic biosensors for rapid point-of-use diagnostic and detection systems in the Human Health, Animal Health and Food Safety sectors. Our LAuRA Plasmonic Sensing Platform enables testing systems that deliver the exceptional sensitivity and quantitative capabilities of lab-based microtiter plate assays with the speed and convenience of lateral flow rapid tests.

At LamdaGen, our vision is to advance the field of plasmonic biosensing by consistently pushing the boundaries of sensitivity, speed, and precision. We remain committed to delivering cutting-edge detection solutions that address critical needs across diverse industries, ultimately improving the quality of human, animal and environmental health.

For additional information, please visit or email